Bionova Scientific aims to set up new Plasmid DNA GMP facility neat Houston, US
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated